And yet you are both right. A year or so ago I recall seeing an interview with one of the senior Genentech guys who basically said if you don’t have a comprehensive data pack there is no discussion to be had. I’m not sure we have ever produced a comprehensive in vivo data pack and the one in-vitro data pack was a year late and it was for the ill-fated MYC programme. The one thing that gave me confidence at the last AGM was the recognition that data packs were everything. So, lets see how they go this year moving from great idea to great product.
The tide is high..., page-44
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.005(2.70%) |
Mkt cap ! $886.5M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 19.0¢ | 17.5¢ | $508.8K | 2.763M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 118941 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 183634 | 2 |
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| PYC (ASX) Chart |
Day chart unavailable